<DOC>
	<DOCNO>NCT00364923</DOCNO>
	<brief_summary>Primary • Determine efficacy pralatrexate concurrent vitamin B12 folic acid supplementation administer patient relapsed refractory peripheral T-cell lymphoma ( PTCL ) Secondary - Determine safety pralatrexate concurrent vitamin B12 folic acid supplementation administer patient relapsed refractory PTCL - Determine pharmacokinetic ( PK ) profile pralatrexate administer vitamin B12 folic acid supplementation</brief_summary>
	<brief_title>Study Pralatrexate With Vitamin B12 Folic Acid Patients With Relapsed Refractory Peripheral T-cell Lymphoma</brief_title>
	<detailed_description>This Phase 2 , single arm , non-randomized , open-label , multi-center study design evaluate safety effectiveness pralatrexate administer vitamin B12 folic acid supplementation patient relapse refractory PTCL . Pralatrexate give 3-5 minute intravenously ( IV ) , mean vein . If pralatrexate tolerate well , patient receive IV injection pralatrexate every week 6 week , follow 1 week without receive pralatrexate . These 7 week cycle repeat depend response tolerability .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<criteria>Histologically/cytologically confirm PTCL , use Revised European American Lymphoma ( REAL ) World Health Organization ( WHO ) disease classification : 1 . T/Natural Killer ( T/NK ) cell leukemia/lymphoma 2 . Adult Tcell lymphoma/leukemia ( human Tcell leukemia virus [ HTLV ] 1+ ) 3 . Angioimmunoblastic T cell lymphoma 4 . Blastic Natural Killer ( NK ) lymphoma ( skin , lymph node , visceral involvement ) 5 . Anaplastic large cell lymphoma , primary systemic type 6 . PTCL unspecified 7 . T/NKcell lymphoma nasal 8 . Enteropathytype intestinal lymphoma 9 . Hepatosplenic T cell lymphoma 10 . Extranodal peripheral T/NKcell lymphoma unspecified 11 . Subcutaneous panniculitis Tcell lymphoma 12 . Transformed mycosis fungoides Documented progression disease least 1 prior treatment . Patients may receive experimental therapy prior therapy . Patient least 1 biopsy initial diagnosis relapse set confirm diagnosis PTCL . Patient recover toxic effect prior therapy . Patients treat monoclonal antibody therapy may enrol regardless time frame therapy progression disease . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . ≥ 18 year age . Adequate hematological , hepatic , renal function . Women childbearing potential must agree practice medically acceptable contraceptive regimen study treatment initiation least 30 day last administration pralatrexate must negative serum pregnancy test within 14 day prior first day study treatment . Patients postmenopausal least 1 year surgically sterilize require test . Men surgically sterile must agree practice medically acceptable contraceptive regimen study treatment initiation least 90 day last administration pralatrexate . Patient give write informed consent . Patient : 1 . Precursor T/NK neoplasms , exception blastic NK lymphoma 2 . T cell prolymphocytic leukemia ( TPLL ) 3 . T cell large granular lymphocytic leukemia 4 . Mycosis fungoides , transform mycosis fungoides 5 . Sézary syndrome 6 . Primary cutaneous CD30+ disorder : Anaplastic large cell lymphoma lymphomatoid papulosis Active concurrent malignancy ( except non melanoma skin cancer carcinoma situ cervix ) . If history prior malignancy , patient must disease free great equal 5 year . Congestive heart failure Class III/IV accord New York Heart Association 's Heart Failure Guidelines . Uncontrolled hypertension . Human immunodeficiency virus ( HIV ) positive diagnosis receive combination antiretroviral therapy . Patient , history , brain metastasis central nervous system ( CNS ) disease . Patient undergone allogeneic stem cell transplant . Patient relapse less 75 day time autologous stem cell transplant . Active uncontrolled infection , underlie medical condition include unstable cardiac disease , serious illness would impair ability patient receive protocol treatment . Major surgery within 2 week study entry . Receipt conventional chemotherapy radiation therapy ( RT ) within 4 week ( 6 week nitrosoureas mitomycin C ) prior study treatment plan use course study . Receipt corticosteroid within 7 day study treatment , unless patient take continuous dose 10 mg/day prednisone least 1 month . Use investigational drug , biologics , device within 4 week prior study treatment plan use course study . Previous exposure pralatrexate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Peripheral T-cell Lymphoma</keyword>
	<keyword>T-cell Lymphoma</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>PDX</keyword>
	<keyword>Pralatrexate</keyword>
	<keyword>Vitamin B12</keyword>
	<keyword>Folic acid</keyword>
</DOC>